Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
AuthorsDuffy, Michael J
AffiliationDepartment of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin, Ireland. Michael.J.Duffy@ucd.ie
*Early Detection of Cancer
Randomized Controlled Trials as Topic
Tumor Markers, Biological/*blood/chemistry/genetics
MetadataShow full item record
CitationAnn Clin Biochem. 2011 Jul;48(Pt 4):310-6. Epub 2011 Apr 27.
JournalAnnals of clinical biochemistry
AbstractAlthough widely used, the value of prostate-specific antigen (PSA) in screening asymptomatic men for prostate cancer is controversial. Reasons for the controversy relate to PSA being less than an ideal marker in detecting early prostate cancer, the possibility that screening for prostate cancer may result in the overdetection and thus overtreatment of indolent disease and the lack of clarity as to the definitive or best treatment for men diagnosed with localized prostate cancer. Although the results from some randomized prospective trials suggest that screening with PSA reduces mortality from prostate cancer, the overall benefit was modest. It is thus currently unclear as to whether the modest benefit of reduced mortality outweighs the harms of overdetection and overtreatment. Thus, prior to undergoing screening for prostate cancer, men should be informed of the risks and benefits of early detection. Newly emerging markers that may complement PSA in the early detection of prostate cancer include specific isoforms of PSA and PCA3.
- PSA in screening for prostate cancer: more good than harm or more harm than good?
- Authors: Duffy MJ
- Issue date: 2014
- Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
- Authors: Rubio-Briones J, Casanova J, Dumont R, Rubio L, Fernandez-Serra A, Casanova-Salas I, Domínguez-Escrig J, Ramírez-Backhaus M, Collado A, Gómez-Ferrer A, Iborra I, Monrós JL, Ricós JV, Solsona E, Salas D, Martínez F, Lopez-Guerrero JA
- Issue date: 2014 May
- The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
- Authors: Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ
- Issue date: 2014 Dec
- Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
- Authors: Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R
- Issue date: 2015 Apr
- [Current results on PSA-based prostate cancer detection].
- Authors: Graefen M, Schlomm T, Steuber T, Sauter G
- Issue date: 2014 Mar